Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 4,800 shares, a decline of 25.0% from the March 15th total of 6,400 shares. Based on an average daily volume of 22,700 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

Emmaus Life Sciences Stock Performance

Emmaus Life Sciences stock remained flat at $0.02 during trading hours on Friday. The company’s stock had a trading volume of 9 shares, compared to its average volume of 42,960. Emmaus Life Sciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.11. The business’s 50 day moving average price is $0.02 and its 200-day moving average price is $0.02. The stock has a market capitalization of $1.02 million, a P/E ratio of -0.18 and a beta of 6.11.

Emmaus Life Sciences (OTCMKTS:EMMA) last released its earnings results on Monday, April 14th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $3.29 million during the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.